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Free radicalsOxidative stress is one of the factors that could explain the pathophysiological mechanism of inﬂammatory
conditions that occur in cardiovascular disease (CVD) and periodontitis. Such inﬂammatory response is often
evoked by speciﬁc bacteria, as the lipopolysaccharide (LPS) of Porphyromonas gingivalis is a key factor in this
process. The aim of this research was to study the role of mitochondrial dysfunction in peripheral blood
mononuclear cells (PBMCs) from periodontitis patients and to evaluate the inﬂuence of LPS on ﬁbroblasts to
better understand the pathophysiology of periodontitis and its relationship with CVD. PBMCs from patients
showed lower CoQ10 levels and citrate synthase activity, togetherwith high levels of ROS production. LPS-treated
ﬁbroblasts provoked increased oxidative stress and mitochondrial dysfunction by a decrease in mitochondrial
protein expression, mitochondrial mass, and mitochondrial membrane potential. Our study supports the
hypothesis that LPS-mediatedmitochondrial dysfunction could be at the origin of oxidative stress in periodontal
patients. Abnormal PBMC performance may promote oxidative stress and alter cytokine homeostasis. In
conclusion, mitochondrial dysfunction could represent a possible link to understanding the interrelationships
between two prominent inﬂammatory diseases: periodontitis and CVD.CoQ10, coenzyme Q10; CVD,
olysaccharide; PD, periodontal
cell; RNS, reactive nitrogen
l rights reserved.© 2011 Elsevier Inc. All rights reserved.Within most cells, the mitochondrion is the main source of
reactive species, which are by-products of cell energy production.
Inside mitochondria the primary reactive oxygen species (ROS)
produced is superoxide, most of which is converted to hydrogen
peroxide by the action of superoxide dismutase. The mitochondrial
production of superoxide has been ascribed to several electron
transport chain enzymes, including complex I and complex III. These
complexes along with coenzyme Q10 (CoQ10) may leak electrons,
which in turn may interact with oxygen, thus forming ROS [1,2]. All
conditions able to alter mitochondrial efﬁciency can enhance ROS
production, with a direct and critical effect on oxidative stress. In this
respect, CoQ10 also has an important lipid-soluble antioxidant activity,
in addition to its well-known redox role as electron/proton carrier,
and is synthesized by the organism under physiological conditions.Oxidative stress is deﬁned as a persistent imbalance between the
production of highly reactive molecular species (e.g., ROS and reactive
nitrogen species (RNS)) and antioxidant defenses [3]. When the
production of ROS/RNS exceeds the capacity of antioxidant defenses,
oxidative stress may have a harmful effect on the functional and
structural integrity of biological tissue. Oxidative stress is involved in
atherosclerosis, hypertension, insulin resistance, heart failure, and the
aging process [3]. Speciﬁcally, mitochondrial oxidative stress has been
related to myocardial dysfunction and heart failure [4]. Most of the
oxidative stress diseases are considered chronic diseases and their
inﬂuence on morbidity and mortality, in the future, will be a critical
public health topic [5]. Among them, cardiovascular diseases (CVDs)
are considered the major cause of death in Western countries [6] and
are related to some risk factors such as obesity, diabetes, insulin
resistance, and metabolic syndrome. Recently, CVDs have also been
associated with an oral disease: periodontitis [7–11]. Periodontitis is a
generally chronic disorder characterized by the breakdown of the
tooth-supporting tissues producing the loss of dentition. The cause is
due to an ecological imbalance between themicrobial bioﬁlm on teeth
and an impaired host inﬂammatory response. One of the main
challenges is the search for factors that may explain these relation-
ships. There is evidence supporting the role of inﬂammation in all the
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Oxidative stress is one of the main factors studied that may be able to
explain the pathophysiological mechanism of inﬂammatory conditions
that occur in atherosclerosis, CVD, and periodontitis. Several studies
have demonstrated an increase in products from oxidative damage in
plasmaand serumof subjectswithperiodontitis comparedwith healthy
individuals [12–14]. Moreover, there is evidence for a decreased
antioxidant capacity in subjectswith periodontitis, evaluated by various
assays [15–17].
Periodontitis, as an infectious disease, has been related also to a
speciﬁc group of bacteria, three of which have been considered the
main periodontal pathogens: Tannerella forsythia, Aggregatibacter
actinomycetemcomitans, and Porphyromonas gingivalis [18]. In the
oral environment the inﬂammatory response is often evoked by
speciﬁc bacteria, such as P. gingivalis, able to produce an inﬂammatory
response that can be correlated with atherosclerosis and ultimately
thrombotic complications [19]. P. gingivalis bacterial DNA has been
found in coronary artery biopsy samples [20]. The lipopolysaccharide
(LPS) of P. gingivalis is a key factor in the development of periodontitis.
Gingival ﬁbroblasts, which are the major constituents of gingival
connective tissue, may directly interact with bacteria and bacterial
products, including LPS, in periodontal lesions. It has been suggested
that gingival ﬁbroblasts play an important role in the host responses
to LPS in periodontal disease [21].
The purpose of this study was to study the role of mitochondrial
dysfunction in peripheral blood mononuclear cells (PBMCs) from
periodontitis patients. The inﬂuence of P. gingivalis LPS was also
investigated in cultured human primary ﬁbroblasts to provide new
approaches that could contribute to the comprehension of the
pathophysiology of periodontitis and its relationship with CVD.
Materials and methods
Patients
A total of 58 patients, all over 35 years of age, attending Seville
University Dental School, were enrolled in the study. All patients who
were accepted gave voluntary written informed consent. Protocol and
consent forms had been previously approved by the Committee of
Ethics and Research of Sevilla University (16 December 2006). All
patients met the following inclusion criteria: they had more than 20
teeth, they had not taken antibiotics or anti-inﬂammatory drugs in the
previous 6 months, they were not affected by immunodeﬁciency, they
were generally healthy, and they had undergone no previous
periodontal treatment. Patients were recruited over a period of
10 months and one blood samplewas taken from each patient as he or
she was recruited.
Routine laboratory tests yielded normal results for glucose 94.7±
8.7 mg/dl (normal values (nv) 76–110), urea 36.3±10.10 mg/dl (nv
10–45), uric acid 5.3±1.2 mg/dl (nv 2.5–7.5), total protein 7.1±
0.4 g/dl (nv 6.6–8.7), creatinine 0.5±0.1 mg/dl (nv 0.5–1.1), aspartate
aminotransferase 24.3±12.5 mU/ml (nv 10–40), alanine amino-
transferase 25.2±15.1 mU/ml (nv 10–40), cholesterol 192.7±
42.3 mg/dl (nv b220), and triglycerides 97.1±44.8 mg/dl (nv 70–
170). Also, blood pressure yielded normal results (systolic blood
pressure 115±10 mmHganddiastolic bloodpressure 70±12 mmHg).
A baseline periodontal examination was performed, and a single
examiner collected full medical and dental histories. A single trained
dental examiner recorded periodontal data. The periodontal probing
depth (PD) and the recession of the gingivalmargin (GM) relative to the
cementoenamel junction at six sites per tooth were recorded. Clinical
attachment level (CAL)was calculatedbyadding recession to PD. PDand
CAL were recorded to the nearest highest millimeter by means of the
North Carolina periodontal probe (Hu-Friedy, Chicago, IL, USA), 15 mm
in length and 0.35 mm in diameter. According to the criteria established
by Machtei et al. [22], the clinical entity of periodontitis is based on thepresence of CAL≥6 mm in two or more teeth and one or more sites
with PD≥5 mm. Patients were divided into two groups: one with
periodontitis (n=38) and the other without periodontitis (n=20).
Blood mononuclear cell and ﬁbroblast cultures
Heparinized and coagulated blood sampleswere collected fromeach
patient and centrifuged at 3800 g for 5 min, and the separated plasma
and serum were stored at −80 °C. PBMCs were puriﬁed by isopycnic
centrifugation using Histopaque-1119 and Histopaque-1077 (Sigma
Chemical Co., St. Louis, MO, USA). Mononuclear cells were cultured at
37 °C in a 5%CO2 atmosphere inRPMI 1640mediumsupplementedwith
L-glutamine, an antibiotic/antimycotic solution (Sigma Chemical Co.),
and 10% fetal bovine serum (Gibco, Invitrogen, Eugene, OR, USA).
Fibroblasts from the skin of healthy volunteers (30 years of age)
were cultured in DMEM (4500 mg/L glucose, L-glutamine, pyruvate;
Gibco, Invitrogen) supplemented with 20% fetal bovine serum (FBS;
Gibco, Invitrogen) and antibiotics (Sigma Chemical Co.). Cells were
incubated at 37 °C in a 5% CO2 atmosphere.
Fibroblast treatment
Fibroblasts were culturedwith 10 μg/ml LPS of P. gingivalis (Nucliber
S.A., Spain) in the absence or presence of a known dose, 30 μM, of CoQ10
for 24 h [23]. LPS used for treatment of cell cultures was diluted with
fetal bovine serum.
Measurement of CoQ10 levels
Lipid extraction from PBMCs and skin ﬁbroblasts was performed as
described previously [23]. Coenzyme Q9 was used as an internal
standard. Brieﬂy, cells were lysedwith 1% SDS and vortexed for 1 min. A
mixture of ethanol:isopropanol (95:5)was added and the sampleswere
vortexed for 1 min. To recover CoQ10, 5 ml of hexane was added and
samples were centrifuged at 1000 g for 5 min at 4 °C. The upper phases
from three different extractions were recovered and dried by a rotatory
evaporator (Rotavapor R-210; Büchi Labortechnik AG, Flawil,
Switzerland). Lipid extract was resuspended in 1 ml ethanol, dried in
a Speed-Vac (Express SC250EXP; Thermo Fisher Scientiﬁc. Waltham,
MA, USA), and kept at−20 °C until used. Samples were suspended in
60 μl of ethanol beforeHPLC injection. Lipid componentswere separated
by a Beckmann 166–126 HPLC system equipped with a 15-cm Kromasil
C-18 column in a column oven set to 40 °C, with a ﬂow rate of 1 ml/min
and a mobile phase containing 65:35 methanol:n-propanol and
1.42 mM lithium perchlorate. CoQ10 levels were analyzed with a UV
detector (System Gold 168; Beckman Coulter, Brea, CA, USA).
Mitochondrial membrane potential (ΔΨm)
PBMCs and ﬁbroblasts were cultured in six-well plates (35-mm-
diameter well) until conﬂuent. MitoTracker (100 nM; MitoTracker
Red CMXRos packing aging; Molecular Probes, Eugene, OR, USA) was
added and incubated for 30 min. Once the incubation was ﬁnished,
the cells were harvested, incubated with fresh medium, washed,
centrifuged (500 g), resuspended in RPMI medium, and analyzed by
ﬂow cytometry in an Epics XL cytometer (Beckman Coulter; excitation
wavelength 579 nm, emission wavelength 599 nm).
Measurement of citrate synthase activity
Citrate synthase-speciﬁc activity in whole-cell extracts prepared
from PBMCs and ﬁbroblasts was measured at 412 nm minus 360 nm
(13.6 mM−1 cm−1) using 5,5-dithiobis-(2-nitrobenzoic acid) to detect
free sulfhydryl groups in coenzyme A as described previously [24].
Table 1
Periodontal data, CoQ10 level, and citrate synthase activity in periodontitis and
nonperiodontitis patients.
Periodontitis (n=38) Nonperiodontitis (n=20)
Age (years) 45±11 44.3±8
BMI (kg/m2) 27.7±2.7 24.6±1.6
CoQ10 (pmol Q /mg protein) 60.2±16* 150.4±13.5
Citrate synthase (EA) 1.9±0.6* 8.6±0.3
Periodontal data
GM 0.79±0.08* 0.18±0.02
PD 3.5±0.5* 1.9±0.2
CAL 4±0.3* 2.1±0.45
Dental plaque 45.1±4.8* 26.4±2.21
Gingival bleeding 60.3±5.3* 41.31±5.9
Data represent the means±SD. BMI, body mass index; CoQ10, coenzyme Q10; EA,
enzymatic activity; CAL, clinical attachment level; GM, recession of the gingival margin;
PD, periodontal probing depth.
*Pb0.001; signiﬁcantly different between periodontitis and nonperiodontitis.
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Whole cellular lysate from ﬁbroblasts was prepared by gentle
shaking with a buffer containing 0.9% NaCl, 20 mM Tris–HCl, pH 7.6,
0.1% Triton X-100, 1 mM phenylmethylsulfonyl ﬂuoride, and 0.01%
leupeptin. Electrophoresis was carried out by 10–15% acrylamide
SDS–PAGE. Proteins were transferred to Immobilon membranes
(Amersham Pharmacia, Piscataway, NJ, USA). Mouse anti-complex I
(39-kDa subunit) and mouse anti-complex III (core 1 subunit)
antibodies were used to detect proteins by Western blotting. Proteins
were electrophoresed, transferred to nitrocellulose membranes, and,
after being blocked overnight at 4 °C, incubated with the respective
antibody solution diluted at 1:1000. Membranes were then probed
with their respective secondary antibody (1:2500). Immunolabeled
proteins were detected by using a chemiluminescence method
(Immun Star HRP substrate kit; Bio-Rad Laboratories, Hercules, CA,
USA). Protein was determined by the Bradford method [25].Mitochondrial ROS production
Mitochondrial ROS generation in PBMCs and ﬁbroblasts was assessed
using MitoSOX red, a red mitochondrial superoxide indicator. MitoSOX
red is a novelﬂuorogenic dye recently developed andvalidated for highly
selective detection of superoxide in the mitochondria of live cells [26].
MitoSOX red reagent is live-cell permeative and is rapidly and selectively
targeted to the mitochondria. Once in the mitochondria, MitoSOX red
reagent is oxidized by superoxide and exhibits red ﬂuorescence.Fluorescence microscopy
Cells grown on microscope slides in six-well plates for 24 h were
incubated with MitoSOX red for 30 min at 37 °C, washed twice in PBS,
ﬁxedwith4%paraformaldehyde in PBS for 0.5–1 hat roomtemperature,
and washed twice with PBS. Cells were then incubated for 10 min at
37 °Cwith anti-cytochrome c antibody (Invitrogen, Barcelona, Spain) to
label mitochondria. Slides were analyzed by immunoﬂuorescence
microscopy (MitoSOX red; excitation wavelength 555/28; emission
wavelength 617/73).Fig. 1. ROS production in periodontitis patients. (A) ROS production was analyzed in
PBMCs from periodontitis and nonperiodontitis patients by ﬂow cytometry as
described under Materials and methods. Data represent the means±SD of three
separate experiments. *Pb0.001 between periodontitis and nonperiodontitis patients.
(B) Effect of CoQ10 on ROS generation. PBMCs of a representative periodontitis patient
and a nonperiodontitis patient were treated with 30 μM CoQ10 for 24 h. Data represent
the means±SD of three separate experiments. *Pb0.001 between periodontitis and
nonperiodontitis; **Pb0.001 between the absence and the presence of CoQ10.Flow cytometry
Approximately 1×106 cells were incubated with 1 μM MitoSOX
red for 30 min at 37 °C, washed twicewith PBS, resuspended in 500 μl
of PBS, and analyzed by ﬂow cytometry in an Epics XL cytometer
(Beckman Coulter; excitation at 510 nm and ﬂuorescence detection
at 580 nm).Analysis of apoptosis
Apoptosis in ﬁbroblasts was assessed by observing nuclei
condensation by Hoechst 33342 (Invitrogen, Molecular Probes)
staining (0.05 μg/ml) and anti-active caspase-3 (Cell Signaling
Technology, Beverly, MA, USA) activation by immunoﬂuorescence
microscopy and Western blot. Ten random ﬁelds and more than 500
cells were counted in each experiment to obtain cell death
percentage considering the number of condensed nuclei. Cells were
grown on 1-mm2 glass coverslips for 24 h in DMEM culture medium
containing 10% FBS. After 24 h treatment, cells were rinsed once with
PBS, ﬁxed in 3.8% paraformaldehyde for 5 min at room temperature,
and permeabilized in 0.1% saponin for 5 min. For immunostaining,
glass coverslips were incubated with anti-active caspase-3 (17 kDa)
antibodies diluted 1:100 in PBS for 1–2 h at 37 °C in a humidiﬁed
chamber. Excess antibody binding was removed by washing the
coverslips with PBS (three times, 5 min). The secondary antibodies, a
tetramethylrhodamine goat anti-rabbit IgG (Molecular Probes)
diluted 1:100 in PBS, were added and incubated for 1 h at 37 °C.
Coverslips were then rinsed with PBS for 3 min, incubated for 1 min
with PBS containing Hoechst 33342 (1 μg/ml), and washed with PBS
(three times, 5 min). Finally, the coverslips were mounted onto
microscope slides using Vectashield mounting medium (Vector
Laboratories, Burlingame, CA, USA) and analyzed using a ﬂuores-
cence microscope (BX 41, Olympus, Barcelona, Spain). Western
blotting was performed using standard methods previously
described.
Fig. 2. Effect of LPS onmitochondrial components. (A) Effect of LPS onmitochondrialmembrane potential (ΔΨm). Fibroblastswere treatedwith 10 μg/ml LPS or 30 μMCoQ10+10 μg/ml LPS for
24 h. (B) Citrate synthase speciﬁc activity in control and LPS-treated PBMCs was assayed as described under Materials andmethods. (C)Mitochondrial protein expression levels in LPS-treated
cells. Proteins (50 μg) from control and treated ﬁbroblast extracts were immunostained with antibodies against complexes I (39-kDa subunit) and III (core 1 subunit). Protein levels were
determined by densitometric analysis (IOD, integrated optical intensity) of three different Western blots and normalized to GAPDH signal. *Pb0.05, between control and LPS-treated cells;
**Pb0.05, between the absence and the presence of CoQ10. (D) CoQ10 level after LPS treatment. Results are expressed as pmol of CoQ10 permg of protein. Data represent themeans±SDof three
separate experiments. *Pb0.01.
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All results are expressed as means±SD unless stated otherwise. The
unpaired Student t test was used to evaluate the signiﬁcance of
differences between groups, accepting Pb0.05 as the level of signiﬁcance.
Results
Clinical data
Thirty-eight of the 58 patients who met the inclusion criteria and
accepted to participate in the study were diagnosed with periodontitis.
Table 1 summarizes the results of the periodontal examination with
signiﬁcant differences in all the parameters studied (Pb0.001 for GM,PD, CAL, dental plaque, and gingival bleeding determinations), whereas
no signiﬁcant differenceswere found for age or bodymass index among
the considered groups.Mitochondrial dysfunction in periodontitis patients
CoQ10 levels, determined in PBMCs isolated from the 38 periodontal
patients, were about 56% lower than in nonperiodontitis patients
(Table 1). To further examinemitochondrial dysfunction in PBMCs from
periodontitis patients, we determined mitochondrial mass by citrate
synthase activity. Table 1 shows a statistically signiﬁcant low level of
citrate synthase activity in PBMC in periodontitis patients (1.99±0.59
sp act) compared to nonperiodontitis patients (8.61±0.27 sp act).
Fig. 3. Effect of LPS on mitochondrial ROS generation. (A) MitoSOX red stain revealed increased superoxide anion. MitoSOX red colocalized with cytochrome c in merged images,
indicating that superoxide anion production occurredmainly inmitochondria. (B) Flow cytometry quantiﬁcation of ROS production. Data represent themeans±SD of three separate
experiments. *Pb0.001, between control and LPS-treated cells; **Pb0.001, between the absence and the presence of CoQ10.
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Quantiﬁcation of ROS production by ﬂow cytometry analysis
showed high levels of mitochondrial ROS production in PBMCs from
periodontitis patients compared to nonperiodontitis patients
(Fig. 1A).
To further examine the role of ROS generation in periodontitis,
PBMCs of one representative patient were incubated with CoQ10, and
mitochondrial ROS production (Fig. 1B) was monitored, showing a
signiﬁcant reduction in mitochondrial ROS production in the presence
of CoQ10.
LPS induces mitochondrial dysfunction in ﬁbroblasts
TheΔΨmwas signiﬁcantly reduced by LPS treatment. Flow cytometry
analysis showed a ΔΨm decrease of about 35% compared to untreated
ﬁbroblasts (Fig. 2A). LPS-induced ΔΨm decrease was also partially
prevented by CoQ10. Fig. 2B shows a statistically signiﬁcant decrease in
citrate synthase activity after LPS treatment compared to controls, also
partially prevented by CoQ10. Enzymatic activity datawere 293.3±4.3 for
control, 261.6±7 for LPS, and 296.4±1.5 for LPS+CoQ10. LPS treatment
induced a signiﬁcant decrease in complex I (39-kDa subunit) and
complex III (core 1 subunit) expression levels with a concomitant
decrease in CoQ10 levels compared to control ﬁbroblasts (67.29±0.8
and 117.244±5.2 pmol/mgprotein, respectively; Figs. 2C andD). CoQ10
supplementation efﬁciently prevented LPS-induced down-regulation of
mitochondrial proteins.LPS induces a high level of mitochondrial ROS production in ﬁbroblasts
MitoSOX red ﬂuorescence colocalized with mitochondrial cyto-
chrome c oxidase (Fig. 3A). Quantiﬁcation of ROS production by ﬂow
cytometric analysis indicated that LPS treatment induced a signiﬁcant
increment inmitochondrial ROSproduction (634.65±9arbitrary units)
compared to control (579.25±18) (Fig. 3B). The addition of a widely
recognized membrane antioxidant, such as CoQ10, attenuated ROS
detection (577.7±7).
LPS initiates the intrinsic pathway of caspase-3-dependent apoptosis in
ﬁbroblasts
LPS caused an increment in apoptotic nuclei condensation and
caspase-3 activation. In contrast, CoQ10 highly prevented the LPS-
induced caspase-3 activation and apoptosis rate (Figs. 4A, B, and C).
Discussion
Oxidative stress and free radical generation, as primary or
secondary events, play important roles in the development of
systemic diseases such as type 2 diabetes, atherosclerosis, and
cardiovascular diseases [27,28], as mitochondria are the major source
of ROS. CoQ10 levels have been suggested to be useful as a
mitochondrial dysfunction marker [29] and CoQ10 deﬁciency has
been found in gingival biopsies and leukocytes from periodontal
patients [30,31]. To assess mitochondrial dysfunction in periodontitis,
Fig. 4. LPS induced apoptosis in ﬁbroblasts treated with LPS 10 μg/ml. (A and B) LPS-induced apoptosis was assessed by caspase-3 activation by immunoﬂuorescence microscopy and
Western blot as described under Materials and methods. (C) LPS-induced apoptosis is prevented by CoQ10. Fibroblasts were treated with 10 μg/ml LPS in the absence or presence of
30 μM CoQ10 for 24 h. Apoptosis was assessed as described under Materials and methods. Data represent the means±SD of three separate experiments. *Pb0.01, between control
and LPS-treated cells; **Pb0.01, between the absence and the presence of CoQ10.
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CoQ10 levels and citrate synthase activity. Interestingly, a positive
correlation between the content of CoQ10 in PBMCs and skeletal
muscle and ﬁbroblasts [32,33] was demonstrated, therefore suggest-
ing that CoQ10 deﬁciency and mitochondrial dysfunction in periodon-
tal patients could also be present in other cells and tissues.
Furthermore, ﬁbroblasts of some patients with CoQ10 deﬁciency
show a higher production of ROS in mitochondria [34]. In this respect,
high levels of mitochondrial ROS production were observed in PBMCs
of our periodontitis patients.
Previouswork has shown that P. gingivalis, one of the key etiological
factors in periodontal pathology, induces oxidative stress in vitro [35],
with bacterial LPS playing a major role in the pathogenesis of
periodontal pathology [36].
To assess themitochondrial damage induced by LPS, we determined
mitochondrial ΔΨm and mitochondrial mass in both control and LPS-
treated ﬁbroblasts. Citrate synthase is a mitochondrial matrix protein
whose activity has been shown to correlate well with mitochondrial
mass [24].We found that LPS treatment in culturedﬁbroblasts provokedincreased oxidative stress andmitochondrial dysfunction, characterized
by a decrease in mitochondrial protein expression, mitochondrial mass,
and CoQ10 levels, aswell as a reduction in themitochondrial membrane
potential.
It has been reported that CoQ10 deﬁciency determined a decrease
in complex II+III, complex III, and complex IV activities; a decrease in
the expression of mitochondrial proteins involved in oxidative
phosphorylation; a decrease in the mitochondrial ΔΨm; and an
increase in ROS production [34]. To study the pathophysiological
mechanisms of LPS-induced mitochondrial dysfunction in cultured
primary ﬁbroblasts, we assessed the expression levels of critical
components of the mitochondrial respiratory chain, observing a
decrement in expression levels of proteins of complex I (39-kDa
subunit) and complex III (core 1 subunit), together with a reduction in
CoQ10 levels.
Next, to investigate the possible mitochondrial origin of ROS
production in relation to periodontitis, LPS-treated and control
ﬁbroblasts were exposed to MitoSOX red, a ﬂuorochrome speciﬁc
for superoxide anion, which is produced in the inner mitochondrial
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treatment. In agreement with the hypothesis that ROS productionwas
caused by a mitochondrial dysfunction, we found that ROS were
mainly generated in mitochondria of LPS-treated ﬁbroblasts.
It should be taken into account that ROS are essential in cells and
tissues for many life-sustaining processes, but they can also induce
cell damage and death [37], especially when their activities are
uncontrolled. ROS can be released into the cytosol and trigger “ROS-
induced ROS release” in neighboring mitochondria. This mitochon-
drion-to-mitochondrion ROS signaling constitutes a positive feed-
back mechanism for enhanced ROS production potentially leading to
signiﬁcant mitochondrial injury [38]. In this context, cytochrome c is
released and procaspase-9, caspase-3, and endonuclease G are
activated, resulting in DNA degradation and apoptotic death. In
our investigation, an increase in apoptosis was observed in LPS-
treated ﬁbroblasts by caspase-3 activation, suggesting that LPS
treatment induces apoptosis by the activation of at least the intrinsic
pathway.
Finally, it can be considered that oxidative stress is one of the key
factors explaining some of the pathophysiological mechanisms
associated with inﬂammatory conditions such as CVD and period-
ontitis [39,40], as lipid peroxidation is one of its most well known
effects. In fact, increased lipid peroxidation has been observed in
periodontitis [8], and it is accepted that lipid peroxidation indirectly
reﬂects intracellular ROS generation. It is interesting to note that
superoxide plays a major role in the release of cytokines (for
example, TNF-α, IL-1β, and IL-6) [41], which are involved in the
pathogenesis of periodontal disease and CVD [7] and this is also
induced by P. gingivalis LPS treatment. The ﬁndings of this study
show that CoQ10 treatment ameliorated mitochondria dysfunction
and oxidative stress and reduced cell death. Because CoQ10 is a
pivotal element in the mitochondrial respiratory chain and, at the
same time, is an important antioxidant, these results suggest that
mitochondrial dysfunction is crucial in the pathophysiology of
periodontal disease.
Our study supports the hypothesis that LPS-mediated mitochon-
drial dysfunction could be at the origin of oxidative stress in
periodontal patients. Abnormal PBMC performance may promote
oxidative stress and alter cytokine homeostasis. In conclusion,
mitochondrial dysfunction could represent a possible link to under-
standing the interrelationships between two prominent inﬂammatory
diseases: periodontitis and CVD.
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